Sugi Predict

Sugi Predict / Compounds / SCHEMBL1060869

SCHEMBL1060869

SCHEMBL1060869

CC(C)N(C(C)C)P(OCc1ccc(Cl)cc1)N(C(C)C)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 3/20 0.42
▸ AGXT P21549 2/20 0.42
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ KMT2A Q03164 1/20 0.37
▸ MAOB P27338 4/20 0.36
▸ APP P05067 1/20 0.36
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ CHRNB2 P17787 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ CCR5 P51681 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5970336 0.86 IDO1 (0.42) IDO1AGXTSLC6A2SLC6A3CA1
SCHEMBL22801194 0.86 IDO1 (0.52) IDO1KMT2A
SCHEMBL21177999 0.84 TDP1 (0.33) IDO1CA2HPGDALDH1A1
SCHEMBL21177998 0.82 IDO1 (0.42) IDO1AGXTSLC6A2SLC6A3CA1
SCHEMBL2252915 0.81 TSHR (0.41) IDO1AGXTSLC6A2SLC6A3CA1
SCHEMBL21178234 0.80 CYP3A4 (0.49) IDO1AGXTMAOBMAOA
SCHEMBL22801241 0.79 APP (0.41) KMT2AAPP
SCHEMBL21179052 0.78 MAOB (0.39) MAOBHTTMAOAALDH1A1
SCHEMBL21178031 0.77 IDO1 (0.49) IDO1SLC6A2SLC6A3KMT2AHTT
SCHEMBL14247542 0.76 IDO1 (0.50) IDO1CA1CA2CA9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025063238-A1 SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN 第一三共株式会社 2025-03-27 — — WO disclosed
WO-2025063239-A1 SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN 第一三共株式会社 2025-03-27 — — WO disclosed
US-11427550-B2 5-fluorouracil compounds NUCORION PHARMACEUTICALS, INC. (US) 2022-08-30 — — US disclosed
US-20200399227-A1 5-FLUOROURACIL COMPOUNDS NUCORION PHARMACEUTICALS, INC. 2020-12-24 — — US disclosed
WO-2019143860-A1 5-FLUOROURACIL COMPOUNDS NUCORION PHARMACEUTICALS, INC. (US) 2019-07-25 — — WO disclosed
EP-2647713-B1 MODIFIED SINGLE-STRAND POLYNUCLEOTIDE DAIICHI SANKYO CO LTD (JP) 2018-02-21 — — EP disclosed
EP-1152009-B2 NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES DAIICHI SANKYO CO LTD (JP) 2017-09-06 — — EP disclosed
US-8987226-B2 Modified single-stranded polynucleotides DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-03-24 — — US disclosed
US-8957201-B2 Oligonucleotide analogues and methods utilizing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-02-17 — — US disclosed
EP-2647713-A1 MODIFIED SINGLE-STRAND POLYNUCLEOTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-10-09 — — EP disclosed
US-7651999-B2 phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer SANKYO COMPANY, LIMITED (JP) 2010-01-26 — — US disclosed
US-20090149404-A1 Oligonucleotide analogues and methods utilizing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-06-11 — — US disclosed
US-7335765-B2 Nucleoside and oligonucleotide analogues DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-02-26 — — US disclosed
US-7314923-B2 Nucleoside and oligonucleotide analogues DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-01-01 — — US disclosed
US-20050261235-A1 2' ,5' -Oligoadenylate analogs SANKYO COMPANY, LIMITED (JP) 2005-11-24 — — US disclosed
EP-1568704-A1 NOVEL 2' ,5' -OLIGOADENYLIC ACID ANALOGUES Sankyo Company, Limited (JP) 2005-08-31 — — EP disclosed
EP-1152009-B1 NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES SANKYO CO (JP) 2005-01-26 — — EP disclosed
US-20030207841-A1 Novel nucleoside and oligonucleotide analogues SANKYO COMPANY LIMITED (JP) 2003-11-06 — — US disclosed
US-20020147332-A1 Novel nucleoside and oligonucleotide analogues SANKYO COMPANY, LIMITED (JP) 2002-10-10 — — US disclosed
EP-1152009-A1 NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES Sankyo Company, Limited (JP) 2001-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399227-A1 5-FLUOROURACIL COMPOUNDS DPYD, DHFR, FAU IDO1 4055/4885AGXT 791/4885SLC6A2 2896/4885
US-20020147332-A1 Novel nucleoside and oligonucleotide analogues RNGTT, NSUN2, MTAP IDO1 3203/4885AGXT 3700/4885SLC6A2 2503/4885
US-20050261235-A1 2' ,5' -Oligoadenylate analogs NSUN2, RNGTT, NSUN3 IDO1 2744/4885AGXT 1691/4885SLC6A2 1734/4885
US-20090149404-A1 Oligonucleotide analogues and methods utilizing the same NSUN2, RNGTT, DUT IDO1 2863/4885AGXT 3107/4885SLC6A2 696/4885
US-11427550-B2 5-fluorouracil compounds DPYD, DHFR, MTHFD1 IDO1 3948/4885AGXT 926/4885SLC6A2 3132/4885
US-20030207841-A1 Novel nucleoside and oligonucleotide analogues RNGTT, NSUN2, MTAP IDO1 3203/4885AGXT 3700/4885SLC6A2 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.